Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

hAd5-S-Fusion+N-ETSD

Vaccine (Adenoviral vector) · Immune activation, directed at SARS-CoV-2 spike protein and SARS-CoV-2 nucleocapsid protein · developed by ImmunityBio

Phase 1/2 Most advanced trial (none active)

IBRX Developer

1 Registered trials

What is hAd5-S-Fusion+N-ETSD?

hAd5-S-Fusion+N-ETSD is a vaccine built on a human adenovirus type 5 vector that encodes SARS-CoV-2 spike and nucleocapsid antigens. The spike gene is optimized for better protein expression, and the nucleocapsid gene carries an enhanced T cell stimulation domain intended to boost cell-mediated immunity. It is studied for COVID-19.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Vaccine (Adenoviral vector)
Targets: SARS-CoV-2 spike protein (antigen), SARS-CoV-2 nucleocapsid protein (antigen)
Mechanism: Immune activation, directed at SARS-CoV-2 spike protein and SARS-CoV-2 nucleocapsid protein
Therapy area: Infectious disease
Developer: ImmunityBio, Inc. (IBRX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04843722	Phase 1/2	Covid19	Withdrawn	IBRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Covid19

More from ImmunityBio

Nogapendekin Alfa Inbakicept FDA approved 5Fluorouracil Phase 2 AAHI-SC2 Phase 1/2 AAHI-SC3 Phase 1/2 Adenoviral Vector Ad5-CEA Vaccine Phase 1/2 agenT-797 Phase 3 Aldoxorubicin Phase 2 CD19 t-haNK Phase 2 ETBX-021 Phase 1/2 ETBX-051 Phase 1/2 ETBX-061 Phase 1/2 ETBX-071 Phase 2

Sources

ClinicalTrials.gov NCT04843722

Updated Oct 11, 2026. Something wrong or missing? Report it on the IBRX page.

Follow IBRX, the company behind hAd5-S-Fusion+N-ETSD

See IBRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IBRX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z